ABSTRACT
A cell-adhesive protein of the human serum, 90K binds galactin-3, beta1-integrins, collagens, and fibronectin, and it is of importance in cell-cell and cell-extracellular matrix adhesion. Serum 90K levels in 137 patients with lymphoma were measured by enzyme-linked immunosorbent assay. Compared with healthy controls, pretreatment serum 90K levels in patients with lymphoma were elevated (P <.001). Of 97 patients who showed objective response to treatment, 20 (21%) had pretreatment 90K levels above the normal cutoff compared with 17 (53%) of 32 patients who did not respond (P =.002). When used as a plastic-immobilized substrate, 90K caused a significant reduction in chemotherapy-induced apoptosis of Jurkat T lymphoma cells. This finding could explain the lack of response in lymphoma patients with high 90K serum levels.
Subject(s)
Antineoplastic Agents/therapeutic use , Carrier Proteins/blood , Cell Adhesion/physiology , Drug Resistance, Multiple , Glycoproteins/blood , Lymphoma/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm , Antineoplastic Agents/toxicity , Apoptosis/drug effects , Biomarkers, Tumor/blood , Cyclophosphamide/toxicity , Doxorubicin/toxicity , Enzyme-Linked Immunosorbent Assay , Female , Humans , Jurkat Cells , Lymphoma/blood , Lymphoma/classification , Lymphoma, B-Cell/blood , Lymphoma, B-Cell/drug therapy , Lymphoma, T-Cell/blood , Lymphoma, T-Cell/drug therapy , Male , Middle Aged , Reference ValuesABSTRACT
BACKGROUND: 90 K is a secreted human serum glycoprotein with immune modulatory activity. METHODS: Serum 90 K levels were determined by an enzyme-linked immunosorbent assay in 19 HIV-1-infected mothers at the time of delivery, in their new-borns (11 HIV-1 infected and eight uninfected), in 26 HIV-1-uninfected mothers and in 86 new-borns of HIV-1-uninfected mothers. RESULTS: 90 K levels in HIV-1-infected transmissive mothers (22.4 +/- 13.9 microg/ml) were similar to those of HIV-1-uninfected mothers (21.1 +/- 7.6 microg/ml; P = 0.715), but lower than those of HIV-1-infected non-transmissive mothers (45.5 +/- 24.8 microg/ml; P = 0.019). The levels were higher in HIV-1-uninfected (47.6 +/- 22.4 mg/ml) than HIV-1-infected (23.7 +/- 15.6 microg/ml; P = 0.014) new-borns of HIV-1-infected mothers. The new-borns of HIV-1-uninfected mothers had lower levels (11.7 +/- 5.3 microg/ml) than both HIV-1-infected and HIV-1-uninfected new-borns of HIV-1-infected mothers (all differences, P < 0.001). CONCLUSION: These results suggest that high 90 K protein serum levels in HIV-1-infected mothers and their new-borns are associated with lack of mother-to-child HIV-1 transmission.
Subject(s)
Carrier Proteins/blood , Glycoproteins/blood , HIV Infections/transmission , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious , Adult , Antigens, Neoplasm , Biomarkers, Tumor , Female , HIV-1/isolation & purification , Humans , Infant, Newborn , PregnancyABSTRACT
Eighty-six children fed human milk were followed prospectively from birth to 12 months of age to assess the effect of milk 90K, a secreted glycoprotein with immune-stimulatory properties, on development of acute respiratory infections (ARI). The level of human milk 90K was inversely related to episodes of ARI (r = - 0.34; P = 0.001). The average 90K level in human milk fed to children who did not develop ARI was significantly higher than in milk fed to children in whom infection occurred on multiple occasions (156.6 +/- 144.8 microg/ml versus 70.9 +/- 92.3 microg/ml; P = 0.001). These data suggest that the protective effects of human milk against ARI may be due in part to immune maturation effects by secreted 90K.
